title: Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture.
abstract: Altered bone microstructure is a major component of osteoporosis and bone fragility. Whilst an important standard by which to diagnose and make treatment decisions for osteoporosis, the evaluation of bone mineral mass by dual-energy X-ray absorptiometry (DXA) at spine or hip is not sufficient for understanding the complex nature of bone microstructure nor to evaluate specific treatment effects on cancellous and cortical bone. Various alternatives to DXA have been developed, enabling the measurement of bone geometry and/or microarchitecture and/or bone strength including hip strength analysis, peripheral and central QCT, 3D analyses of iliac crest bone biopsies, and more recently HR-pQCT, which allows longitudinal assessment of bone microstructure at the distal radius and tibia. The efficacy of treatments for osteoporosis can be evaluated using these techniques. A true improvement of bone microstructure above baseline has not been demonstrated with anti-resorptive treatments; however, they may prevent the decay of cancellous bone and, potentially, cortical thinning. Anabolic agents such as parathyroid hormone (PTH) increase cancellous bone volume and cortical thickness; however, the improvement of cortical bone strength by PTH may be limited by an increase in cortical porosity. Strontium ranelate has been shown to improve not only the trabecular network but also cortical thickness, contributing to its anti-fracture efficacy at vertebral, non-vertebral, and hip sites.
authors.affiliation: Service of Bone Diseases, Geneva University Hospital (HUG), 24 rue Micheli-du-Crest, 1211, Geneva, Switzerland. serge.ferrari@medecine.unige.ch
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
mesh_terms: D000368:Aged; D001706:Biopsy; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
references.citation: Osteoporos Int. 2004 Feb;15(2):103-7
references.pmid: 14605802
references.citation: J Bone Miner Res. 2008 Apr;23(4):463-74
references.pmid: 18052756
references.citation: Osteoporos Int. 2008 Apr;19(4):399-428
references.pmid: 18266020
references.citation: J Bone Miner Res. 2001 Oct;16(10):1846-53
references.pmid: 11585349
references.citation: Bone. 2004 Apr;34(4):736-46
references.pmid: 15050906
references.citation: J Bone Miner Res. 2007 Jan;22(1):149-57
references.pmid: 17042738
references.citation: J Bone Miner Res. 2006 Jan;21(1):124-31
references.pmid: 16355281
references.citation: J Bone Miner Res. 2005 Sep;20(9):1548-61
references.pmid: 16059627
references.citation: Bone. 2009 Mar;44(3):413-7
references.pmid: 19071239
references.citation: J Bone Miner Res. 2003 Nov;18(11):1932-41
references.pmid: 14606504
references.citation: Calcif Tissue Int. 2003 Nov;73(5):423-32
references.pmid: 12964065
references.citation: Lancet. 2002 May 25;359(9320):1841-50
references.pmid: 12044392
references.citation: Bone. 2002 Nov;31(5):620-5
references.pmid: 12477578
references.citation: J Bone Miner Res. 2010 Mar;25(3):472-81
references.pmid: 19778182
references.citation: Bone. 2005 Jun;36(6):948-58
references.pmid: 15878318
references.citation: J Clin Invest. 1997 Sep 15;100(6):1475-80
references.pmid: 9294113
references.citation: J Bone Miner Res. 2008 Jan;23(1):6-16
references.pmid: 17892374
references.citation: J Bone Miner Res. 2009 Apr;24(4):737-43
references.pmid: 19113929
references.citation: Best Pract Res Clin Rheumatol. 2009 Dec;23(6):741-53
references.pmid: 19945686
references.citation: J Clin Endocrinol Metab. 2008 Jul;93(7):2594-601
references.pmid: 18430772
references.citation: J Bone Miner Res. 2007 Mar;22(3):425-33
references.pmid: 17181395
references.citation: J Bone Miner Res. 2008 Feb;23(2):205-14
references.pmid: 17937534
references.citation: Curr Med Res Opin. 2005 Feb;21(2):185-94
references.pmid: 15801989
references.citation: J Bone Miner Res. 2008 Feb;23(2):215-22
references.pmid: 17922612
references.citation: J Bone Miner Res. 2008 May;23(5):730-40
references.pmid: 18251704
references.citation: Osteoporos Int. 2010 Feb;21(2):263-73
references.pmid: 19455271
references.citation: Osteoporos Int. 2009 Jun;20(6):911-21
references.pmid: 18830555
references.citation: Osteoporos Int. 2009 Oct;20(10):1683-94
references.pmid: 19152051
references.citation: J Bone Miner Res. 2009 Aug;24(8):1358-68
references.pmid: 19338452
references.citation: J Bone Miner Res. 2009 Mar;24(3):468-74
references.pmid: 19016592
references.citation: J Bone Miner Res. 2007 Dec;22(12):1885-92
references.pmid: 17680721
references.citation: J Clin Endocrinol Metab. 2005 Dec;90(12):6508-15
references.pmid: 16189253